GLP-1 Drugs and Menopause: What We Know About Ozempic, Wegovy, and HRT

If you use, or are considering, both a GLP-1 medication and menopausal hormone therapy, the evidence specific to that combination remains limited. The drug labels provide general guidance about oral medications, while two small retrospective studies provide early evidence about weight-loss outcomes.

That's not because the question isn't important. It's because the research is still catching up to what's happening in real life. But there is emerging evidence, and it matters. Here's what we know so far, what we don't, and what you should be discussing with your provider.

An underresearched overlap

Many women in midlife are weighing a GLP-1 medication and hormone therapy at the same time. In February 2026 the FDA began approving labeling changes for menopausal hormone therapy products, one product at a time, that removed some of the boxed warning language from those labels. The boxed warning about endometrial cancer stays on systemic estrogen-alone products, and the contraindications did not change. Many of the women asking about both are dealing with metabolic changes and hormonal decline at once.

Midlife weight and body composition change for several overlapping reasons. Longitudinal SWAN data found that total weight did not begin accelerating at the menopause transition, although fat gain increased, lean mass declined, and fat distribution shifted toward the abdomen around that period. Aging, activity, eating patterns, sleep, stress, medications, and health conditions can also affect weight and metabolic health.

But here's the disconnect: the major GLP-1 clinical trials (STEP, SURMOUNT, SUSTAIN) were not designed around menopause, and they did not report whether concurrent HRT changes the response. A later post hoc analysis of the SURMOUNT trials compared tirzepatide results across reproductive stages, but it did not answer the HRT question. So the data gap is real.

How menopause affects GLP-1 response

Human evidence does not establish that menopause makes GLP-1 medications less effective. A post hoc analysis of the SURMOUNT program found substantial tirzepatide-associated weight reduction in premenopausal, perimenopausal, and postmenopausal groups. Because reproductive stage was classified retrospectively and concurrent HRT was not the question being tested, that analysis cannot determine whether estrogen levels or HRT alter an individual's response.

What the human evidence can support

The direct human evidence comes from two small retrospective Mayo Clinic cohorts discussed below. They found an association between existing hormone-therapy use and greater weight loss with semaglutide or tirzepatide, but they did not assign hormone therapy randomly or test a mechanism. Clinician experience and metabolic theories cannot establish that starting HRT improves GLP-1 response.

Do GLP-1 drugs interact with HRT?

FDA prescribing information does not identify a drug interaction specific to menopausal hormone therapy. Semaglutide and tirzepatide delay gastric emptying and their labels discuss possible effects on oral medications. Semaglutide did not produce a clinically relevant interaction with the oral drugs tested. Tirzepatide gives specific temporary backup instructions for oral hormonal contraceptives, but that evidence should not be rewritten as a menopausal-HRT warning.

This does not make every combination risk-free. Each medication's contraindications and warnings still apply. If menopause symptoms change after starting or increasing a GLP-1 medication, ask the prescriber or pharmacist to review the complete regimen. Do not change the route or dose based only on a theoretical absorption concern.

Other practical considerations:

• Nausea: Nausea can occur with GLP-1 medications and may also occur with oral progesterone, but evidence here does not establish that taking them together amplifies it. Report persistent or severe symptoms to the prescriber. Do not change progesterone route or dose without clinical guidance, because an inadequate regimen may fail to protect the uterine lining during systemic estrogen treatment.
• Bone health: Substantial weight loss can be accompanied by bone loss. Menopausal hormone therapy prevents bone loss and fracture in appropriate candidates, but studies have not established that concurrent HRT produces a net bone benefit during GLP-1 treatment. Bone-density testing should follow an individualized osteoporosis risk assessment.
• Lean mass: Body-composition substudies report some absolute lean-mass loss during GLP-1-associated weight loss. DXA lean mass is not the same as skeletal muscle, and the proportion varies by study. Resistance exercise, adequate nutrition, and monitoring of strength or function may be appropriate parts of a clinician-guided weight-management plan.

What the combination evidence can tell us

Two retrospective cohorts found greater average weight loss among postmenopausal GLP-1 users who were already using hormone therapy. These associations are hypothesis-generating. They do not prove that HRT caused the difference, identify a biological mechanism, or show that starting HRT will improve weight loss.

Menopausal hormone therapy should be considered for established menopause indications after an individualized assessment of benefits, risks, and contraindications. The current evidence does not support starting it solely to make a GLP-1 medication work better.

A Mayo Clinic study of 106 postmenopausal women taking semaglutide, published in Menopause in 2024, found that those also using hormone therapy lost about 16% of their body weight over 12 months, against about 12% for those on semaglutide alone. A separate 2026 Mayo study of tirzepatide, in The Lancet Obstetrics, Gynaecology & Women's Health, pointed the same way. Both are observational - they show an association rather than proving hormone therapy caused the difference - so treat this as a reason to raise the question with your clinician, not as a guarantee.

What about tirzepatide (Mounjaro/Zepbound)?

Tirzepatide, the dual GIP/GLP-1 receptor agonist marketed as Mounjaro for diabetes and Zepbound for weight management, has shown even stronger weight loss results than semaglutide (Ozempic/Wegovy) in clinical trials. The same considerations apply regarding menopause and HRT interactions.

Notably, the SURMOUNT-2 trial enrolled adults with type 2 diabetes, and a subgroup analysis did look at results by sex. Women on tirzepatide lost significant weight, but the study didn't differentiate by menopause status. Future research is needed.

Preserving lean mass during weight loss

Lean mass can decline with aging, across the menopause transition, and during substantial weight loss. The amount varies, and loss of DXA-measured lean mass does not by itself establish sarcopenia or functional decline. Resistance exercise and adequate nutrition are the most directly supported strategies discussed here.

Evidence that menopausal hormone therapy independently preserves muscle mass is mixed. A meta-analysis of 12 randomized trials found no significant overall benefit for lean body mass. Physiologic-dose testosterone has not demonstrated significant improvements in lean body mass, total body fat, or muscle strength in women. Its only evidence-based indication is postmenopausal hypoactive sexual desire disorder after formal assessment, not preservation of muscle during weight loss.

If you're on a GLP-1 drug, talk to your provider about:

• A resistance-training plan appropriate for your health, experience, and mobility
• A protein and calorie target tailored to your nutritional needs and medical history
• Whether tracking strength, physical function, or body composition would change your care
• Whether you have bone-health risks that require assessment

What to ask your doctor

If you're on both GLP-1 medications and HRT - or considering starting either - here are the questions worth bringing to your next appointment:

• If I use oral HRT, should we monitor symptoms or another clinical endpoint after starting or increasing my GLP-1 medication?
• Do I have bone, nutrition, or muscle-function risks that need assessment during weight loss?
• What do the two small observational cohorts mean for my care, without assuming that HRT caused the difference?
• Is any laboratory monitoring indicated for a specific medication or medical condition?
• What's our plan for maintaining weight loss if I stop the GLP-1 drug?

The bottom line

The intersection of GLP-1 treatment and menopause remains underresearched. Women using both treatments have little prospective evidence tailored to their situation.

FDA labels do not identify an interaction specific to menopausal hormone therapy, although their general oral-medication warnings and each drug's other contraindications still apply. Two small retrospective cohorts found greater weight loss among women already using hormone therapy, but they cannot show that HRT caused the difference or that starting HRT would improve GLP-1 response.

The most important thing you can do is find a provider who understands both menopause and metabolic health - someone who won't treat these as two separate problems being managed in two separate silos. Your hormones and your metabolism are deeply connected, and your care should reflect that.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider about your individual treatment plan, especially when combining medications.